Medgadget previously reported on Zilico’s device for cancer detection in 2009 as a multi-centre clinical trial was underway. While the device might have changed names from APX to Zedscan, Zilico has received the CE Mark approval for its commercial distribution in Europe. The ZedScan is able to help accurately diagnose cervical cancer based on the differences in electrical resistance between normal, pre-cancerous, and cancerous tissue. This fact is what inspired the ZedScan name. The” Z” is the symbol for impedence, “E” stands for the EIS (electrical impedance spectroscopy) technology , “D” for device, and “Scan” because that’s what it does.
Between 2000 and 2013, five clinical studies have been conducted using the ZedScan and its previous incarnations, for a total of 920 patients recruited. Colposcopists had a 73.6% HG-CIN detection success rate, but multiple biopsies were required to achieve this. When using the ZedScan to assist in identifying potential cancerous areas, the rate jumped to 88.5% and required only a single biopsy. By increasing the accuracy on the very first attempt, ZedScan reduces the number of biopsies required. This clearly has both clinical benefits as well as economic ones.
Flashback: Zilico Handheld System for Rapid Cervical CA Diagnosis…
Product page: ZedScan I…
